Status: Recruiting
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
Participants needed: 480
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eleison Pharmaceuticals LLC.Updated: Dec 31, 2024Locations: 3
Eligibility criteria
At least 18 years of age [+8]
More than one prior systemic therapy regimen for metastatic pancreatic cancer (r... [+24]